Below is a listing of all sessions the speaker is scheduled to present.
Enterprise Project Leader
GE Healthcare Lifesciences
Speaker BioDaniella is the Enterprise Projects Leader within GE Healthcare Life Sciences, a global business within GE Healthcare focused on platform and turn key solutions for vaccines, biodefense and blood plasma production. The Enterprise Projects team provides biopharma equipment, consumables, services and training & education for biopharma customers and ministries of health globally through tailored end-to-end solutions. Prior to her current role, she held the position of Senior Strategic Marketing Leader for GE Healthcare's ReadyToProcessTM product platform. Previously, Daniella was a co-founder of WAVE Biotech, LLC, and involved in the characterization, commercialization and product development of the WAVE Bioreactor. As Vice President, Global Sales & Marketing for WAVE, she led integration efforts upon the acquisition of WAVE by GE Healthcare. She has held research positions in environmental remediation at Cytec and cell culture at Schering-Plough Corporation. Daniella has a B.E. degree in Chemical Engineering from Stevens Institute of Technology, and is currently an Executive MBA candidate at New York University Stern School of Business.
|Wednesday, March 30, 2011|
The baculovirus production technology can support safe and expeditious vaccine production and provides an attractive alternative to the current egg-based influenza vaccine (TIV) manufacturing process. Protein Sciences Corporation was initially awarded a $34.5 million contract in June 2009 for an 18 month period from the U.S. Department of Health and Human Services to further develop this technology for the production of recombinant influenza vaccines for pandemic preparedness with the contract recently extended for another two year period.
The manufacturing process for FluBlok/PanBlok, a recombinant protein based influenza vaccine including the combination of single- and multi-use equipment in the current process will be described.
Possible scenarios for establishing surge capacity range from warm base manufacturing facilities (ready to go when they need to), to facilities used for the production of other products that can be rapidly deployed when needed through a hybrid approach, to fully disposable factories. The panel will evaluate advantages, and disadvantages of each scenario from a financial, regulatory, and engineering perspective.